COLL COLLEGIUM PHARMACEUTICAL, INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1267565 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY7.7%
TTM net income YoY-34.7%
TTM EPS YoY-37.9%
Revenue 3-yr CAGR14.2%
Net income 3-yr CAGR61.8%
Margins
Gross margin59.0%
Operating margin15.2%
Net margin4.7%
FCF margin41.3%
EBITDA margin15.7%
Returns
ROE13.4%
ROA2.1%
ROIC (approx.)81.3%
Asset turnover0.44x
Leverage & solvency
Liabilities / assets85.9%
Debt / equity0.00x
Current ratio1.01x
Interest coverage1.62x
Cash quality & payout
Operating cash flow / net income8.86x
Accruals ratio-16.2%
Payout ratio—
Capex / revenue0.2%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q42025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $216.34M | $199.88M | $193.52M | $205.45M | $209.36M | $188.00M | $177.76M | $181.95M |
| Cost of revenue | $90.92M | $89.59M | $76.27M | $77.07M | $80.19M | $79.62M | $80.43M | $83.66M |
| Gross profit | $125.42M | $110.29M | $117.25M | $128.38M | $129.17M | $108.38M | $97.32M | $98.29M |
| SG&A expense | $99.59M | $106.59M | $86.35M | $67.64M | $67.10M | $73.64M | $76.42M | $63.09M |
| Operating income | $28.72M | $3.70M | $30.90M | $60.76M | $62.09M | $35.10M | $21.69M | $38.11M |
| Interest expense | $21.94M | $19.52M | $15.86M | $19.29M | $21.77M | $20.46M | $20.79M | $22.65M |
| Pretax income | $7.91M | -$13.53M | $18.74M | $29.04M | $43.44M | $17.02M | $3.12M | $17.27M |
| Income tax | -$13.85M | $1.52M | $4.24M | $12.07M | $11.93M | $5.04M | $705,000 | $4.73M |
| Net income | $21.76M | -$15.05M | $14.50M | $16.96M | $31.51M | $11.98M | $2.42M | $12.54M |
| EBITDA | $29.21M | $5.51M | $31.36M | $61.68M | $63.12M | $36.24M | $22.78M | $39.15M |
| EPS (basic) | 0.69 | -0.46 | 0.45 | 0.54 | 1.00 | 0.38 | 0.08 | 0.39 |
| EPS (diluted) | 0.60 | -0.46 | 0.40 | 0.46 | 0.84 | 0.34 | 0.07 | 0.36 |
| Weighted avg. shares (diluted) | 39.11M | 32.46M | 40.07M | 40.08M | 39.44M | 39.08M | 32.84M | 40.11M |
| Balance sheet | ||||||||
| Cash & equivalents | $144.80M | $129.47M | $268.65M | $231.25M | $150.10M | $117.35M | $96.19M | $96.61M |
| Short-term investments | $0 | $0 | $153.10M | $155.43M | $135.77M | $104.81M | $101.58M | $92.20M |
| Receivables | $310.79M | $285.10M | $228.76M | $211.33M | $233.95M | $213.02M | $228.71M | $228.54M |
| Inventory | $88.20M | $113.27M | $42.74M | $40.91M | $38.05M | $38.15M | $37.22M | $35.56M |
| Current assets | $611.75M | $608.01M | $745.67M | $691.41M | $613.87M | $549.21M | $527.55M | $482.26M |
| PP&E, net | $10.88M | $10.65M | $11.66M | $12.01M | $12.25M | $12.90M | $13.85M | $14.33M |
| Goodwill | $193.88M | $190.18M | $145.93M | $145.93M | $145.93M | $147.94M | $150.76M | $162.33M |
| Intangibles | $1.13B | $1.19B | $614.04M | $669.51M | $724.98M | $780.46M | $835.93M | $891.40M |
| Total assets | $2.10B | $2.14B | $1.65B | $1.66B | $1.61B | $1.59B | $1.63B | $1.66B |
| Current liabilities | $603.09M | $589.86M | $434.97M | $440.03M | $452.93M | $464.61M | $486.71M | $509.51M |
| Total liabilities | $1.80B | $1.82B | $1.34B | $1.36B | $1.33B | $1.36B | $1.40B | $1.43B |
| Shareholders' equity | $296.44M | $311.91M | $312.42M | $301.68M | $274.81M | $232.21M | $234.43M | $228.84M |
| Shares outstanding | 31.07M | 32.50M | 32.41M | 31.71M | 31.60M | 31.55M | 32.13M | 31.44M |
| Cash flow statement | ||||||||
| Operating cash flow | $86.54M | $71.32M | $57.11M | $123.05M | $78.44M | $72.44M | $55.40M | $84.64M |
| Capital expenditure | $277,000 | $496,000 | $270,000 | $689,000 | $188,000 | $65,000 | $798,000 | $570,000 |
| Free cash flow | $86.26M | $70.83M | $56.84M | $122.36M | $78.25M | $72.37M | $54.60M | $84.07M |
| Investing cash flow | -$277,000 | -$502.59M | $1.63M | -$20.07M | -$30.87M | -$2.92M | -$9.68M | -$11.76M |
| Financing cash flow | -$70.93M | $292.09M | -$21.34M | -$21.82M | -$14.82M | -$48.37M | -$25.24M | -$41.28M |
| Depreciation & amortization | $491,000 | $1.81M | $463,000 | $923,000 | $1.03M | $1.14M | $1.09M | $1.04M |
| Stock-based compensation | $12.45M | $14.48M | $10.88M | $9.75M | $9.81M | $10.82M | $11.52M | $7.60M |
| Share buybacks | — | $0 | — | $0 | $0 | $25.10M | — | $25.02M |
Free plan shows the latest 8 periods; Pro shows all 51 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.